Cinacalcet: pharmacological and clinical aspects

Bibliography

• Silverberg SJ, Shane E, Jacobs TP, et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999;341:1249-55
   PubMed Web of Science ®Google Scholar
• Weigel RJ. Nonoperative management of hyperparathyroidism: present and future. Curr Opin Oncol 2001;13:33-8
   PubMed Web of Science ®Google Scholar
• Drüeke T. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure nephrology forum 1995;48:259-72
   Google Scholar
• Malluche H, Faugere MC. Renal bone disease 1990: an unmet challenge for the nephrologists. Kidney Int 1990;38:193-211
   PubMed Web of Science ®Google Scholar
• Amann K, Ritz E, Wiest G, et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814-9
   PubMed Web of Science ®Google Scholar
• Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 1997;4:212-24
   PubMedGoogle Scholar
• Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. AmJ Physiol 1997;273:F925-30
   PubMed Web of Science ®Google Scholar
• Fadda GZ, Hajjar SM, Perna AF, et al. On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest 1991;87:255-61
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
   PubMed Web of Science ®Google Scholar
• Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J kidney Dis 2000;35:1226-37
   PubMed Web of Science ®Google Scholar
• Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial 2003;16:140-7
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation: K/DOQI clinical practice guidelines on bone metabolism and disease. Am J Kidney Dis 2003;42(S3):1-201
   PubMed Web of Science ®Google Scholar
• Andress DL, Norris KC, Coburn JW, et al. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321:274-9
   PubMed Web of Science ®Google Scholar
• Martin KJ, Gonzalez EA, Gellens M, et al. 19-nor-1-a-25-dihydroxyvitamin D2(paricalcitol) safely and effectively reduces the levels of PTH in patients with hemodialysis. J Am Soc Nephrol 1998;9:1427-32
   PubMed Web of Science ®Google Scholar
• Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001;59:1187-201
   PubMed Web of Science ®Google Scholar
• Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87
   PubMed Web of Science ®Google Scholar
• Ringer S. A further contribution regarding the influence of different constituents of the blood on the contraction of the heart. J Physiol 1883;4:29-43
   PubMedGoogle Scholar
• Shoback DM, Thatcher J, Leombruno R, Brown EM. Relationship between parathyroid hormone secretion and cytosolic calcium concentration in dispersed bovine parathyroid cells. Proc Natl Acad Sci USA 1984;81:3113-7
   PubMed Web of Science ®Google Scholar
• Brown EM. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messenger. Physiol Rev 1991;71:371-411
   PubMed Web of Science ®Google Scholar
• Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575-80
   PubMed Web of Science ®Google Scholar
• Brown EM, Vassilev PM, Quinn S, Hebert SC. G-protein-coupled,extracellular Ca(2+)-sensing receptor: a versatile regulator of diverse cellular functions. Vitam Horm 1999;55:1-71
   PubMed Web of Science ®Google Scholar
• Chang W, Shoback D. Extracellular Ca2+ sensing receptors – an overview. Cell Calcium 2004;35:183-96
   PubMed Web of Science ®Google Scholar
• Breitwieser GE, Miedlich SU, Zhang M. Calcium sensing receptors as integrators of multiple metabolic signals. Cell Calcium 2004;35:209-16
   PubMed Web of Science ®Google Scholar
• Bai M. Structure-function relationship of the extracellular calcium-sensing receptor. Cell Calcium 2004;35:197-207
   PubMed Web of Science ®Google Scholar
• Coburn JW, Elangovan L, Goodman WG, Frazao JM. Calcium-sensing receptor and calcimimetic agents. Kidney Int 1999;S73:52-8
   Google Scholar
• Ward Donald T. Calcium receptor-mediated intracellular signalling Cell Calcium 2004;35:217-28
   PubMed Web of Science ®Google Scholar
• Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Dis 2000;1:307-15
   PubMedGoogle Scholar
• Ba Jianming, Friedman Peter A. Calcium-sensing receptor regulation of renal mineral ion transport. Cell Calcium 2004;35:229-37
   PubMed Web of Science ®Google Scholar
• Dvorak MM, Riccardi D. Ca(2+) as an extracellular signal in bone. Cell Calcium 2004;35:249-55
   PubMed Web of Science ®Google Scholar
• Pi M, Quarles LD. Osteoblast Calcium-Sensing Receptor has characteristics of ANF/7TM receptors. J Cell Biochem 2005;95:1081-92
   PubMed Web of Science ®Google Scholar
• Hebert SC, Cheng S, Geibel J. Functions and roles of the extracellular Ca(2+)-sensing receptor in the gastrointestinal tract. Cell Calcium 2004;35:239-47
   PubMed Web of Science ®Google Scholar
• Thakker RV. Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium 2004;35:275-82
   PubMed Web of Science ®Google Scholar
• Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983;56:572-81
   PubMed Web of Science ®Google Scholar
• Cetani F, Picone A, Cerrai P, et al. Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2000;85(12):4789-94
   PubMed Web of Science ®Google Scholar
• Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51:328-36
   PubMed Web of Science ®Google Scholar
• Brown EM, Wilson RE, Eastman RC, et al. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 1982;54:172-9
   PubMed Web of Science ®Google Scholar
• Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-sensing receptor extression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 1999;55:1284-92
   PubMed Web of Science ®Google Scholar
• Malberti F, Faina M, Imbasciati E. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999;14:2398-406
   PubMed Web of Science ®Google Scholar
• Messa P, Vallone C, Mioni G, et al. Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. Kidney Int 1994;46:1713-20
   PubMed Web of Science ®Google Scholar
• Nemeth E, Fox I. Calcimimetics compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 1999;10:66-71
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Steffey ME, Hammerland LG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-5
   PubMed Web of Science ®Google Scholar
• Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 1998;53:223-7
   PubMed Web of Science ®Google Scholar
• Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436-45
   PubMed Web of Science ®Google Scholar
• Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004;308:627-35
   PubMed Web of Science ®Google Scholar
• Kumar GN, Sproul C, Poppe L, et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004;32:1491-500
   PubMed Web of Science ®Google Scholar
• Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmacodynamic, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis 2004;44:1070-6
   PubMed Web of Science ®Google Scholar
• Rothe HM, Shapiro WB, Sun WY, Chou SY. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet Genomics 2005;15:29-34
   PubMedGoogle Scholar
• Amgen Inc. Cinacalcet (Sensipar) US prescribing information [online]. URL: Available from: http://www.sensipar.com
   Google Scholar
• Padhi D, Salfi M, Harris RZ. The Pharmacokinetics of Cinacalcet are unaffected following consumption of high- and low-fat meals. Am J Ther 2007;14:235-40
   PubMedGoogle Scholar
• Balfour JAB, Scott LJ. Cinacalcet Hydrochloride. Drugs 2005;65:271-81
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7
   PubMed Web of Science ®Google Scholar
• Serra AL, Braun SC, Starke A, et al. Pharmacokinetics and Pharmacodynamics of Cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 2008;8:803-10
   PubMed Web of Science ®Google Scholar
• Nakashima D, Takama H, Ogasawara Y, et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of destromethorphan: in vitro and clinical studies. J Clin Pharmacol 2007;47:1311-9
   PubMed Web of Science ®Google Scholar
• Evenepoel P. calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int 2008;74:265-75
   PubMed Web of Science ®Google Scholar
• Shoback DM, Bilezikian JP, Turner SA, et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:5644-9
   PubMed Web of Science ®Google Scholar
• Peacock M, Bilezikian JP, Klassens PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, Rubin MR, Faiman C, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inperable parathyroid carcinoma. J Clin Endocrinol Metab 2007;92:3803-8
   PubMed Web of Science ®Google Scholar
• Sajid-Crocket S, Singer FR, Hershman JM. Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 2008;57:517-21
   PubMed Web of Science ®Google Scholar
• Iglesias P, Ais G, Gonzalez A, et al. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy. Am J Med Sci 2008;335:111-4
   PubMed Web of Science ®Google Scholar
• Falchetti A, Cilotti A, Vaggelli L, et al. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab 2008;4:351-7
   PubMedGoogle Scholar
• Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24
   PubMed Web of Science ®Google Scholar
• Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-83
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003
   Google Scholar
• Block GA, Martin KJ, De Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
   PubMed Web of Science ®Google Scholar
• Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005;20:2186-93
   PubMed Web of Science ®Google Scholar
• Messa P, Macario F, Yagoob M, et al. The optima study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
   PubMed Web of Science ®Google Scholar
• Strippoli GFM, Palmer S, Tong A, et al. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 2006;47:715-26
   PubMed Web of Science ®Google Scholar
• Malluche HH, Moner-Faugere MC, Wang G, et al. An assessment of cinacalcet HCl effects on bone histology i dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008;69:269-77
   PubMed Web of Science ®Google Scholar
• Lien YHH, Silva AL, Whittman D. Effects of Cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1232-7
   PubMed Web of Science ®Google Scholar
• Ureña Torres P. Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 2004;19(Suppl 5):v27-33
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
   PubMed Web of Science ®Google Scholar
• Shalhoub V, Shatzen E, Henley C, et al. Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols. Calcif Tissue Int 2006;79:431-42
   PubMed Web of Science ®Google Scholar
• Lopez J, Mendoza FJ, Agulera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008;73:300-7
   PubMed Web of Science ®Google Scholar
• Messa P, Alberti L, Como G, et al. Calcimimetic increases osteoprotegerin and decreases fetuin-A levels in dialysis patients. Nephrol Dial Transplant 2007;22:2724-5
   PubMed Web of Science ®Google Scholar
• Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacaclet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007;2:898-905
   PubMed Web of Science ®Google Scholar
• Charytan C, Coburn JW, Chonchol M, et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005;46:58-67
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8
   PubMed Web of Science ®Google Scholar
• De Francisco ALM, Pinera C, Palomar R. Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract [Online pub 27 May 2008]
   Google Scholar
• Coyne DW. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract [Online pub 13 May 2008]
   Google Scholar
• Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998;54:1704-13
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single centre study. Nephrol Dial Transplant 2004;19:1281-7
   PubMed Web of Science ®Google Scholar
• Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005;5:1934-41
   PubMed Web of Science ®Google Scholar
• Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2006;21:1736
   Google Scholar
• Szwarc I, Argilés A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006;82:675-80
   PubMed Web of Science ®Google Scholar
• Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007;22:2362-5
   PubMed Web of Science ®Google Scholar
• Falck P, Vethe NT, Asberg A, et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008;23:1048-53
   PubMed Web of Science ®Google Scholar
• Peng LW, Logan JL, James SH, et al. Cinacalcet-associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient. Am J Med 2007;120:e7-9
   PubMedGoogle Scholar
• Mohammed IA, Sekar V, Bubtana AJ, et al. Proximal calciphylaxis treated with calcimimetic ‘Cinacalcet’. Nephrol Dial Transplant 2008;23:387-9
   PubMed Web of Science ®Google Scholar
• Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005;67:467-76
   PubMed Web of Science ®Google Scholar
• Pattaragarn A, Foz J, Alon US. Effect of the calcimimeticNPS R-467 on furosemide-induced nephrocalcinosis in the young rat. Kidney Int 2004;65:1684-9
   PubMed Web of Science ®Google Scholar
• Piecha G, Kokeny G, Nakagawa K, et al. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 2008;294:F748-57
   PubMed Web of Science ®Google Scholar
• Garside R, Pitt M, Anderson R, et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007;22:1428-36
   PubMed Web of Science ®Google Scholar
• Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007;49:801-13
   PubMed Web of Science ®Google Scholar